Core Viewpoint - WuXi AppTec has emerged as a leader in the global XDC outsourcing service industry, providing comprehensive R&D and production services from its Wuxi base and expanding to Singapore [1][2]. Industry Summary - The global XDC market is experiencing rapid growth, with the ADC market also expanding significantly. The growth rate in the Chinese market surpasses the global average, driven by advancements in technology that address efficacy and safety issues of ADC drugs [1][2]. - In 2024, 60% of new XDC trials globally will be initiated by Chinese companies, highlighting China's active role in the licensing of XDC-related drugs [2]. Company Summary - WuXi AppTec's total revenue is projected to grow from 311 million yuan in 2021 to 4.052 billion yuan in 2024, reflecting a compound annual growth rate (CAGR) of 135% [2]. - As of the first half of 2025, the company has 19 projects in Phase III clinical trials and 11 in the PPQ stage, with a backlog of orders amounting to 1.329 billion USD, a 58% year-on-year increase [2][3]. - The company is investing heavily in capital expenditures, with over 1.5 billion yuan planned for 2024 and an expected total of over 7 billion yuan from 2026 to 2029 to support R&D and commercial production [3]. - WuXi AppTec is at the forefront of XDC innovation, developing competitive technology platforms such as WuXiDARx conjugation platform and X-LinC linker platform [3]. - The company is rated as a "buy" with a target price of 74.0 HKD, with projected revenue growth of 45.7%, 35.7%, and 30.9% for 2025E, 2026E, and 2027E respectively [3].

Investment Rating - The report maintains a "Buy" rating for the company [4] Core Views - The company has raised its full-year revenue guidance from 35% to 45% due to strong order backlog and capacity release [8] - The company is a global leader in ADC CRDMO with significant long-term growth potential, leading to an adjusted target price of HKD 65.82 [2] - The company plans to increase long-term capital expenditures to expand domestic and international capacity, with cumulative capital expenditures expected to exceed RMB 7 billion by 2029 [8] Financial Forecasts - Revenue projections for 2025-2027 have been adjusted to HKD 5.876 billion, HKD 8.062 billion, and HKD 10.693 billion, respectively, reflecting growth rates of 45.0%, 37.2%, and 32.6% [3] - The adjusted earnings per share for 2025-2027 are forecasted to be HKD 1.29, HKD 1.78, and HKD 2.45, respectively [2] - The gross margin is expected to improve to 34.9% by 2025, with net profit margin stabilizing around 26.4% [3] Market Performance - The company's stock price as of August 21, 2025, was HKD 59.05, with a 52-week high of HKD 64.45 and a low of HKD 17.90 [4] - The company has shown strong absolute performance over the past year, with a 220.58% increase [5]

Macro Strategy - Public fiscal expenditure in June showed a year-on-year growth rate of 0.38%, with a cumulative growth rate of 3.4% for the first half of the year, maintaining around 4% overall. However, the fiscal revenue and expenditure gap for the first half of the year was -25,705 billion, higher than the -20,658 billion in the same period of 2024, indicating no improvement in fiscal conditions [2][3] - The LPR remained unchanged in July, with the one-year LPR at 3.00% and the five-year LPR at 3.50%. This stability aligns with market expectations, reflecting the positive effects of the LPR adjustment made in May [2][3] Stock Market Overview - A-share indices showed a fluctuating upward trend from July 21 to July 25, with the Shanghai Composite Index rising by 1.67%, the Shenzhen Component Index by 2.33%, and the ChiNext Index by 2.76%. The STAR Market Index saw the highest weekly fluctuation at 4.36% [3][5] - The market's upward momentum is primarily driven by the commencement of the Yarlung Tsangpo River downstream hydropower project, boosting infrastructure-related sectors, and the continued strength of the technology sector. The GDP growth for the first half of the year was 5.3% year-on-year, laying a foundation for the market's upward trend [5][6] Investment Recommendations - The A-share market is expected to operate in a "slow bull" manner in 2025, supported by policies aimed at stabilizing the stock market and overlapping trends from the new "National Nine Articles" and similar to the "Four Trillion" investment [7] - Key sectors to focus on in 2025 include technology, green energy, consumption, and infrastructure, as highlighted in the government work report [7] - In the short term, the market may experience downward adjustments in August due to uncertainties surrounding US-China tariff negotiations, despite the overall positive economic performance in the first half of the year [7] North Exchange Overview - As of July 25, 2025, the North Exchange had 268 listed stocks, with an average total market value of 8,520.87 billion, an increase of 2.36% from the previous week [9][10] - The liquidity of the North Exchange improved significantly, with an average trading volume of 1.427 billion shares, up 39.13%, and an average trading value of 31.082 billion, up 42.36% [10] Industry Insights Semiconductor Industry - The company Micron is leveraging an AI+SaaS strategy to enhance its platform and integrated development path, significantly improving its competitive advantage. In 2024, the AI+SaaS business revenue reached 842 million, accounting for 54% of total revenue [32][33] - The marketing SaaS market in China is projected to grow from 35.6 billion in 2024 to 74.5 billion by 2027, with a CAGR of 29.3%, indicating substantial growth potential [33] Pharmaceutical Industry - The ADC (Antibody-Drug Conjugate) market is experiencing explosive growth, with the global market size expected to rise from 7.9 billion in 2022 to 14.1 billion in 2024, and projected to exceed 68.5 billion by 2030, reflecting a CAGR of 30.1% [26][27] - The CDMO (Contract Development and Manufacturing Organization) sector is becoming increasingly essential due to the high technical barriers of ADC drugs, with the market size expected to grow from 0.1 billion in 2018 to 2.1 billion in 2022, and projected to reach 2.45 billion by 2030 [27][28] Investment Suggestions - The semiconductor sector is expected to benefit from the growth of KA clients and the rapid deployment of AI applications, leading to a high growth period for the company's SaaS business [36] - In the pharmaceutical sector, companies with ADC-related technology reserves, such as WuXi AppTec and Haoyuan Pharmaceutical, are recommended for investment due to their significant growth potential in the CDMO space [30][31]

Investment Rating - The report initiates coverage with a "Buy" rating for WuXi XDC [1][3][4] Core Insights - The global ADC CRDMO market is expanding, with the company benefiting from a growing order pipeline and a dual-factory strategy that enhances capacity and customer retention. The company is also entering the XDC market to create a second growth curve [3][4][5] Summary by Sections Company Overview - WuXi XDC is a leading end-to-end ADC CRDMO provider, benefiting from high industry demand and a growing order book. The projected EPS for 2024-2026 is 0.89, 1.24, and 1.66 CNY respectively, with a target price of 43.4 CNY based on a 35X PE for 2025 [4][16] Market Dynamics - The global ADC drug market is expected to grow to 64.7 billion USD by 2030, with a CAGR of 30% from 2022 to 2030. The outsourcing market for ADC and broader bioconjugates is projected to reach 11 billion USD by 2030, with a CAGR of 28% [4][40] Financial Performance - The company has shown strong revenue growth, with revenues increasing from 311 million CNY in 2021 to an estimated 2.124 billion CNY in 2023, representing a CAGR of 180.7%. The net profit is expected to grow significantly, reaching 1.067 billion CNY in 2024 [8][31] Production Capacity and Strategy - The company is implementing a dual-factory strategy to enhance global production capacity, with new facilities in Singapore expected to be operational by the end of 2025. The company has 18 clinical stage III projects and is advancing its ADC pipeline [5][19][37] Growth Opportunities - The XDC market is emerging, with significant potential in non-oncological indications. The company is strategically positioned to capitalize on this growth by leveraging its existing technology and expanding its project and client base [5][21][22]